Valirx eyes partnerships as first VAL201 study hits the mark

Valirx eyes partnerships as first VAL201 study hits the mark

Source: 
Pharmaforum
snippet: 

Shares in UK biotech Valirx were up sharply this morning after its lead drug VAL201 showed evidence of efficacy in advanced prostate cancer in its first clinical trial.